[Pharm-policy] BMS Taxol Monopoly - 9 percent of company value?

[James Love]

Apparently investors think that the Bristol Monopoly patent on Taxol, a
US governemnt funded drug, are responsible for about 9 percent of the
value of the company.  That was the drop in price of BMS shares when it
lost key claims to patents on treatment regimes for Taxol.   Jamie

-----
>From srctran@world.std.com Fri Mar  3 04:37:54 2000
Date: Fri, 3 Mar 2000 03:00:34 -0500 (EST)
From: Gregory Aharonian <srctran@world.std.com>
Reply-To: patent-news@europe.std.com
To: patent-news@world.std.com
Subject: PATNEWS: $80,000 egg; Taxol; Konrad; Stupid BizPat; More on    Amazon

!20000303  $80,000 egg; Taxol; Konrad; Stupid BizPat; More on Amazon

    --  Judge invalidates most patent protection for Taxol uses


                              ====================

    --  JUDGE INVALIDATES MOST PATENT PROTECTION FOR TAXOL USES

Thursday's Wall Street Journal reports that Federal Judge William Wall in
Newark, granted several pretrial motions by generic drug companies seeking
to invalidate patent protection for any use of Taxol except for ovarian
cancer patients.  Bristol Myers, the patent assignee, plans to appeal,
with its stock dropping $5 (9%) during the day.


James Love, Consumer Project on Technology    
P.O. Box 19367        | http://www.cptech.org 
Washington, DC 20036  | love@cptech.org       
Voice 202/387-8030    | Fax 202/234-5176